Beyond estrogen, selective ER modulators like tamoxifen (TAM) and the pure ER down‐regulator fulvestrant (FUL), commonly used in ER+ breast cancer, also have a high affinity for GPER, mimicking estrogen's effects in breast cancer. Here, GPER1 is linked to breast cancer.